CORT CORCEPT THERAPEUTICS INC

Nasdaq corcept.com


$ 74.56 $ -1.67 (-2.19 %)    

Wednesday, 22-Oct-2025 10:35:14 EDT
QQQ $ 606.85 $ -3.95 (-0.65 %)
DIA $ 467.90 $ -1.32 (-0.28 %)
SPY $ 669.09 $ -2.83 (-0.42 %)
TLT $ 91.87 $ -0.12 (-0.13 %)
GLD $ 371.68 $ -1.19 (-0.32 %)
$ 75.39
$ 76.19
$ 74.52 x 1
$ 74.69 x 82
$ 74.50 - $ 76.19
$ 42.01 - $ 117.33
739,437
na
7.94B
$ 0.46
$ 60.18
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-05-2025 03-31-2025 10-Q
3 02-26-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 07-29-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-15-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-15-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-23-2021 12-31-2020 10-K
20 11-03-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 05-04-2020 03-31-2020 10-Q
23 02-24-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-02-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 02-28-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-02-2017 03-31-2017 10-Q
35 03-06-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-corcept-therapeutics-maintains-145-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintain...

 reported-sunday-corcept-highlights-rosella-late-breaker-relacorilant-plus-nab-paclitaxel-improves-pfs-and-os-in-platinum-resistant-ovarian-cancer

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall su...

 in-an-sec-filing-on-tuesday-corcept-therapeutics-said-on-friday-the-company-announced-the-termination-of-the-distribution-agreement-with-optime-care-8k

As previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distributor of Korlym and t...

 hc-wainwright--co-reiterates-buy-on-corcept-therapeutics-maintains-145-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintain...

 4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

 what-analysts-are-saying-about-corcept-therapeutics-stock

Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opin...

 canaccord-genuity-maintains-buy-on-corcept-therapeutics-maintains-140-price-target

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ: CORT) with a Buy and maintains $140 price targ...

 corcept-therapeutics-to-present-new-data-from-pivotal-phase-3-rosella-trial-of-relacorilant-plus-nab-paclitaxel-in-patients-with-platinum-resistant-ovarian-cancer-at-2025-esmo

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medicat...

 canaccord-genuity-maintains-buy-on-corcept-therapeutics-raises-price-target-to-140

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target fr...

 fda-accepts-corcepts-nda-for-relacorilant-in-platinum-resistant-ovarian-cancer-sets-pdufa-date-for-july-11-2026

FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026Corcept Therapeutics Incorporated (NASDAQ:CORT), a co...

 canaccord-genuity-maintains-buy-on-corcept-therapeutics-lowers-price-target-to-137

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target fr...

 piper-sandler-maintains-overweight-on-corcept-therapeutics-lowers-price-target-to-121

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweight and lowers the price tar...

 corcept-therapeutics-lowers-fy2025-sales-guidance-from-900000m-950000m-to-850000m-900000m-vs-899047m-est

Financial Results"The second quarter marked another period of robust growth in our hypercortisolism business. Once again, w...

 corcept-therapeutics-q2-eps-029-beats-019-estimate-sales-194430m-miss-199395m-estimate

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION